RT Journal Article
SR Electronic
T1 Screening and vaccination against COVID-19 to minimize school closure
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.15.21261243
DO 10.1101/2021.08.15.21261243
A1 Colosi, Elisabetta
A1 Bassignana, Giulia
A1 Contreras, Diego Andrés
A1 Poirier, Canelle
A1 Boëlle, Pierre-Yves
A1 Cauchemez, Simon
A1 Yazdanpanah, Yazdan
A1 Lina, Bruno
A1 Fontanet, Arnaud
A1 Barrat, Alain
A1 Colizza, Vittoria
YR 2021
UL http://medrxiv.org/content/early/2021/12/11/2021.08.15.21261243.abstract
AB Schools were closed extensively in 2020-2021 to counter COVID-19 spread, impacting students’ education and well-being. With highly contagious variants expanding in Europe, safe options to maintain schools open are urgently needed. We developed an agent-based model of SARS-CoV-2 transmission in school. We used empirical contact data in a primary and a secondary school, and data from pilot screenings in 683 schools during the 2021 spring Alpha wave in France. We fitted the model to observed school prevalence to estimate the school-specific reproductive number and performed a cost-benefit analysis examining different intervention protocols. We estimated RAlpha=1.40 (95%CI 1.35-1.45) in the primary and RAlpha=1.46 (1.41-1.51) in the secondary school during the wave, higher than Rt estimated from community surveillance. Considering the Delta variant and vaccination coverage in Europe, we estimated RDelta=1.66 (1.60-1.71) and RDelta=1.10 (1.06-1.14) in the two settings, respectively. Under these conditions, weekly screening with 75% adherence would reduce cases by 34% (95%CI 32-36%) in the primary and 36% (35-39%) in the secondary school compared to symptom-based testing. Insufficient adherence was recorded in pilot screening (median ≤53%). Regular screening would also reduce student-days lost up to 80% compared to reactive closure. Moderate vaccination coverage in students would still benefit from regular screening for additional control (23% case reduction with 50% vaccinated children). COVID-19 pandemic will likely continue to pose a risk for school opening. Extending vaccination coverage in students, complemented by regular testing largely incentivizing adherence, are essential steps to keep schools open, especially under the threat of more contagious variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially funded by: ANR projects COSCREEN (ANR-21-CO16-0005) and DATAREDUX (ANR-19-CE46-0008-03); ANRS project EMERGEN (ANRS0151); EU H2020 grants MOOD (H2020-874850) and RECOVER (H2020-101003589); EU HORIZON grant VERDI; REACTing COVID-19 grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Contact studies were approved by the Commission Nationale de l'Informatique et des Libertés (CNIL, the French national body responsible for ethics and privacy) and school authorities. Informed consent was obtained from participants or their parents if minors. No personal information of participants was associated with the RFID identifier. Testing at school was part of surveillance activities approved by school authorities and proposed with parental consent. Data on adherence to screening were aggregated and anonymized at school level.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available at the references cited.